Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024

Description

Non-alcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease, distinguished by inflammation of the liver, and has the potential to progress to cirrhosis and liver failure.

Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-alcoholic steatohepatitis (nash) market size has grown exponentially in recent years. It will grow from $3.33 billion in 2023 to $4.54 billion in 2024 at a compound annual growth rate (CAGR) of 36.3%. The expansion observed in the previous period can be ascribed to the increasing incidence of non-alcoholic steatohepatitis (NASH), the surge in obesity rates, heightened awareness and diagnostic efforts, changes in lifestyle and dietary habits, and advancements in healthcare infrastructure development.

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $14.53 billion in 2028 at a compound annual growth rate (CAGR) of 33.7%. Anticipated growth in the forecast period is driven by advancements in NASH drug development, increased screening initiatives, higher healthcare spending, collaborative research, and government support. Key trends include a focus on lifestyle interventions, enhanced collaboration in clinical research, regulatory advancements, and the integration of artificial intelligence in diagnosis and monitoring.

The escalating prevalence of obesity is fueling the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation, poses significant health concerns, representing body weight that exceeds healthy or standard levels for a person of a given height. The increasing incidence of non-alcoholic fatty liver disease, driven by the obesity pandemic, positions NASH as a potential leading cause of severe liver disease in the coming decades. This heightened risk underscores the growing need for NASH treatment and related pharmaceuticals. As reported in the COVID-19 and Obesity, The 2021 Atlas published by the World Obesity Federation in April 2021, over 60% of the US population was recorded as overweight. Furthermore, the report projected an expected increase in obesity rates to 44.2% for males and 44.4% for females in the US population by 2025. This data highlights the alarming rise in obesity cases, reinforcing the anticipated growth trajectory of the Non-Alcoholic Steatohepatitis (NASH) market as a consequence of the obesity epidemic.

The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Technological advancement is a pivotal trend gaining traction in the non-alcoholic steatohepatitis (NASH) market, with major players in the industry actively pursuing technological innovations to sustain their positions. An illustrative example is the initiative undertaken by GENFIT Inc., a France-based biotechnology company, in May 2021. GENFIT launched NASHnext, a novel non-invasive test designed for diagnosing non-alcoholic steatohepatitis (NASH). NASHnext leverages the power of NIS4TM, an exclusive screening technology developed by GENFIT, utilizing a groundbreaking blood-based molecular biomarker test for the detection of NASH and severe fibrosis. This advanced diagnostic test is currently available exclusively in the United States and Canada through Labcorp, a prominent global life sciences company. By integrating cutting-edge technology into diagnostic solutions, companies such as GENFIT aim to enhance the accuracy and efficiency of NASH diagnosis, reflecting the broader trend of technological innovation within the non-alcoholic steatohepatitis market.

Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-B selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.

In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.

Major companies operating in the non-alcoholic steatohepatitis (nash) market report are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Cempra Pharmaceuticals Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Vivus LLC, Arisaph Pharmaceuticals Inc., Galectin Therapeutics Inc., Raptor Pharmaceutical Inc., VERVA Technologies Pvt. Ltd., Viking Therapeutics, Conatus Pharmaceuticals Inc., One Way Liver S.L., BioPredictive S.A.S., Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2023. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Solid; Liquid
2) By Product: Vitamin E and Pioglitazone; Ocaliva; Elafibranor; Selonsertib and Cenicriviroc; Other Products
3) By Disease Cause: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
4) By Sales Channel: Hospital Pharmacy; Retail Pharmacy; Online Provider
5) By Application: Oral; Parenteral
Companies Mentioned: NGM Biopharmaceuticals Inc.; Novartis AG; AstraZeneca plc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r15867

1. Executive Summary

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Non-Alcoholic Steatohepatitis (NASH) Market Size and Growth

5.1. Global Non-Alcoholic Steatohepatitis (NASH) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

6.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Solid
Liquid
6.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Vitamin E and Pioglitazone
Ocaliva
Elafibranor
Selonsertib and Cenicriviroc
Other Products
6.3. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hypertension
Heart Disease
High Blood Lipid
Type 2 Diabetes
Obesity
6.4. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Provider
6.5. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral

7. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

7.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

8.1. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Alcoholic Steatohepatitis (NASH) Market

9.1. China Non-Alcoholic Steatohepatitis (NASH) Market Overview
9.2. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Alcoholic Steatohepatitis (NASH) Market

10.1. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis (NASH) Market

11.1. Japan Non-Alcoholic Steatohepatitis (NASH) Market Overview
11.2. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis (NASH) Market

12.1. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

13.1. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

14.1. South Korea Non-Alcoholic Steatohepatitis (NASH) Market Overview
14.2. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

15.1. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
15.2. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Alcoholic Steatohepatitis (NASH) Market

16.1. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis (NASH) Market

17.1. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Alcoholic Steatohepatitis (NASH) Market

18.1. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis (NASH) Market

19.1. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis (NASH) Market

20.1. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

21.1. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
21.2. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis (NASH) Market

22.1. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Alcoholic Steatohepatitis (NASH) Market

23.1. North America Non-Alcoholic Steatohepatitis (NASH) Market Overview
23.2. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Alcoholic Steatohepatitis (NASH) Market

24.1. USA Non-Alcoholic Steatohepatitis (NASH) Market Overview
24.2. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis (NASH) Market

25.1. Canada Non-Alcoholic Steatohepatitis (NASH) Market Overview
25.2. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Alcoholic Steatohepatitis (NASH) Market

26.1. South America Non-Alcoholic Steatohepatitis (NASH) Market Overview
26.2. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

27.1. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

28.1. Middle East Non-Alcoholic Steatohepatitis (NASH) Market Overview
28.2. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis (NASH) Market

29.1. Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview
29.2. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

30.1. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape
30.2. Non-Alcoholic Steatohepatitis (NASH) Market Company Profiles
- 30.2.1. NGM Biopharmaceuticals Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novartis AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AstraZeneca plc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. GlaxoSmithKline plc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. F. Hoffmann-La Roche AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

31.1. The Takeda Pharmaceutical Company Limited
31.2. Gilead Sciences Inc.
31.3. Novo Nordisk A/S
31.4. Genfit SA
31.5. Cadila Pharmaceuticals Ltd.
31.6. Intercept Pharmaceuticals Inc.
31.7. Enanta Pharmaceuticals Inc.
31.8. Blade Therapeutics Inc.
31.9. Cempra Pharmaceuticals Inc.
31.10. Galmed Pharmaceuticals Inc.
31.11. Immuron Limited
31.12. Terns Pharmaceuticals Inc.
31.13. Tobira Therapeutics Inc.
31.14. Arena Pharmaceuticals Inc.
31.15. Vivus LLC

32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking

33. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

35. Non-Alcoholic Steatohepatitis (NASH) Market Future Outlook and Potential Analysis

35.1 Non-Alcoholic Steatohepatitis (NASH) Market In 2028 - Countries Offering Most New Opportunities
35.2 Non-Alcoholic Steatohepatitis (NASH) Market In 2028 - Segments Offering Most New Opportunities
35.3 Non-Alcoholic Steatohepatitis (NASH) Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer